Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Abstract Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib. Methods Data were from two phase 3 studies, OPAL Broaden (12 months) and OPAL Beyond (6 months). P...

Full description

Bibliographic Details
Main Authors: Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Arthritis Research & Therapy
Subjects:
Arthritis
Psoriatic
Anti-rheumatic agents
Online Access:https://doi.org/10.1186/s13075-022-02721-0

Similar Items

Similar Items